Clinical trials: Pulmonary Hypertension, Primary
Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
What is this study about? This study will test whether adding sotatercept to usual medicines for pulmonary arterial hypertension (PAH) can help adults who have PAH due to unrepaired congenital heart defects (atrial or ventricular…
- Trial name
- SuMILE (NCT07356778)
- Testing
- Sotatercept, vasodilator-based PAH therapy
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Kazuya Hosokawa
Pulmonary Arterial Hypertension
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
The primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
- Trial name
- SCOBA-PH (NCT01330108)
- Testing
- ambrisentan
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Arterial Hypertension
Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic…
- Trial name
- Biomarkers (NCT00566423)
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Northwell Health
Pulmonary Arterial Hypertension, Right Heart Failure
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension.
- Trial name
- REHAB-PH (NCT03554291)
- Testing
- Famotidine 20 MG
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Washington
Pulmonary Arterial Hypertension
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the…
- Trial name
- STRIDE-3 (NCT00811018)
- Testing
- Sitaxsentan
- Where
- 91 sites in United States, Argentina and 14 more
- Volunteers
- 1,192 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension (PAH)
(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
Pilot study to determine the therapeutic effect of two prarallel groups treated with either Riciguat or Macitentan, evaluated by the change in systolic and diastolic RV function within 12 weeks after first drug intake in order to…
- Trial name
- RightHeartIII (NCT03362047)
- Testing
- Riciguat Group, Macitentan Group
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- University of Giessen
Healthy Volunteers, Pulmonary Arterial Hypertension
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
- Trial name
- NCT06649110
- Testing
- LTP
- Where
- 87 sites in United States, Argentina and 16 more
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension, Cardiovascular Diseases (CVD)
Pulmonary Arterial Hypertension and Associated Cardiovascular Disease Detection Using Artificial Intelligence
Cardiovascular disease (CVD) is a leading global cause of morbidity and mortality and excessive healthcare expenditures. Pulmonary hypertension (PH) represents an insidious and progressive subset of CVD affecting an estimated 1%…
- Trial name
- PULSAR (NCT07147725)
- Testing
- AI Stethoscope
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension
Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)
Patients with pulmonary arterial hypertension (PAH) are at much higher risk of death if the RV (right ventricle) is weak. The purpose of this study is to get a better understanding of the factors that determine RV adaptation and…
- Trial name
- ISS (NCT02074449)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Sarcoidosis, Pulmonary Arterial Hypertension
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.
- Trial name
- NCT00403650
- Testing
- Iloprost
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Pulmonary Arterial Hypertension
Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)
Pulmonary arterial hypertension (PAH) is a rare lung disease that leads to elevated blood pressure in the lungs and strain on the right side of the heart.
- Trial name
- WATERLOO (NCT07700303)
- Testing
- Discontinuation of parenteral prostacyclins analogues or selexipag
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- University of Alberta
Pulmonary Arterial Hypertension
Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide
This is an open label phase 2 pilot study designed to evaluate the safety, tolerability and device performance of the GeNO nitrosyl delivery system during right heart catheterization (RHC) in participants with pulmonary arterial…
- Trial name
- PILOT (NCT01092559)
- Testing
- Nitric Oxide generated by the GeNO nitrosyl delivery system
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Geno LLC
High Altitude, Six-minute Walk Test
Assessment of Six-minute Walking Distance 6MWD Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of descent from high altitude (Quito Ecuador: 2850m) to sea level on six-minute walking distance and scores in healthy individuals, who live permanently >2600m.
- Conditions
- High Altitude, Six-minute Walk Test, High Altitude Effects, Healthy
- Trial name
- NCT07801872
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Systemic Sclerosis
Hemodynamic Changes in Connective Tissue Disease
The study serves the identification of early forms of pulmonary arterial hypertension (PAH) in connective tissue disease and the hemodynamic follow-up of the investigated patients.
- Trial name
- NCT01468792
- Where
- Austria
- Volunteers
- 85 people
- Sponsor
- Medical University of Graz
Pulmonary Arterial Hypertension
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT04791514
- Testing
- Treprostinil Palmitil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.
- Trial name
- IMPROVE-PAH (NCT07365332)
- Testing
- IKT-001
- Where
- 43 sites in United States, Argentina and 12 more
- Volunteers
- 486 people
- Sponsor
- Inhibikase Therapeutics
Hypertension, Pulmonary
Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
This is an observational study to monitor the continued effectiveness of Ventavis (inhaled iloprost) in the long-term. The study observes the effects and the safety of Ventavis inhalation therapy over at least 2 years and up to 4…
- Trial name
- NCT00250640
- Testing
- Iloprost (Ventavis, BAYQ6256)
- Where
- 43 sites in France, Germany and 4 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension (PAH)
Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension
The goals of this study were two-fold. First, the attempt to quantify the relationships between pulmonary arterial stiffness, right ventricular function and the efficiency of ventricular-vascular interactions in patients with…
- Trial name
- NCT03523910
- Testing
- Magnetic Resonance Imaging (MRI) with exercise
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Pulmonary Arterial Hypertension
To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers
The purpose of this study is to compare the pharmacokinetics of two Traclear 62.5 mg tablets and one HGP1206 125 mg tablet in healthy male volunteers.
- Trial name
- NCT01864863
- Testing
- HGP1206, Traclear
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pulmonary Arterial Hypertension
Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic illness characterized by increased pulmonary pressures resulting in right heart failure and premature death.
- Trial name
- NCT02080533
- Testing
- Slow-paced respiration therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania